tiprankstipranks
Trending News
More News >
Indegene Limited (IN:INDGN)
:INDGN
India Market
Advertisement

Indegene Limited (INDGN) AI Stock Analysis

Compare
2 Followers

Top Page

IN:INDGN

Indegene Limited

(INDGN)

Select Model
Select Model
Select Model
Neutral 66 (OpenAI - 4o)
Rating:66Neutral
Price Target:
₹597.00
▲(7.97% Upside)
Indegene Limited's strong financial performance is the primary driver of its overall score, supported by robust revenue growth and a solid balance sheet. However, technical indicators suggest a bearish trend, and the stock appears overvalued with a high P/E ratio and low dividend yield, which weigh down the overall score.

Indegene Limited (INDGN) vs. iShares MSCI India ETF (INDA)

Indegene Limited Business Overview & Revenue Model

Company DescriptionIndegene Limited operates as a life sciences commercialization company in India and internationally. It helps biopharmaceutical, emerging biotech, and medical device companies develop products, get to the market, and grow impact through the life cycle. The company offers enterprise commercial solutions, enterprise medical solutions, enterprise clinical solutions, omnichannel activation solutions, and NEXT technology platforms. The company was incorporated in 1998 and is based in Bengaluru, India.
How the Company Makes MoneyIndegene makes money primarily through its service-based and product-based revenue models. The company's key revenue streams include providing strategic advisory services, technology platforms, and managed services to pharmaceutical companies, biotech firms, medical device manufacturers, and healthcare payers. Indegene partners with its clients to deliver customized solutions that optimize clinical development, accelerate time-to-market for new therapies, and enhance patient engagement. Additionally, strategic partnerships and collaborations with leading healthcare organizations contribute significantly to its earnings by expanding its reach and enhancing its service offerings.

Indegene Limited Financial Statement Overview

Summary
Indegene Limited demonstrates strong financial health with consistent revenue growth and profitability, supported by a solid balance sheet structure and effective cash flow management. The company benefits from high margins and a stable equity position. However, potential risks include volatility in cash flow activities and occasional inconsistencies in net income growth.
Income Statement
88
Very Positive
Indegene Limited has demonstrated robust revenue growth over the years, with a notable increase in total revenue from 2021 to 2025. The company's EBIT and EBITDA margins have shown strong performance, reflecting efficient cost management. However, the sharp decline in EBITDA in 2025 warrants attention. The gross profit margin remains consistently high, indicating a solid business model. Net profit margin is healthy, although net income growth has varied, suggesting some volatility.
Balance Sheet
82
Very Positive
The company maintains a strong equity base, as indicated by the high stockholders' equity and a low debt-to-equity ratio in recent years, reflecting financial stability. The equity ratio is substantial, implying significant ownership of assets financed by equity. The reduction in total debt and the increase in assets over the years are positive indicators. However, fluctuations in liabilities and equity suggest some balance sheet instability that requires monitoring.
Cash Flow
75
Positive
Operating cash flow has remained strong, aligning well with net income, indicating good cash conversion efficiency. Free cash flow has grown, reflecting improved operational efficiency, although the growth rate in free cash flow has been inconsistent. The company has managed its capital expenditures efficiently, but the volatility in investing and financing cash flows suggests potential risks in cash flow management.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue29.24B28.39B25.90B23.06B16.65B9.66B
Gross Profit23.43B7.72B25.31B5.81B6.10B9.66B
EBITDA6.41B5.34B5.84B4.54B2.66B2.64B
Net Income4.35B4.07B3.37B2.66B1.65B1.49B
Balance Sheet
Total Assets0.0033.26B25.46B22.04B13.53B5.96B
Cash, Cash Equivalents and Short-Term Investments16.64B16.64B9.85B7.11B6.26B1.33B
Total Debt0.001.02B4.90B5.03B657.52M513.88M
Total Liabilities-26.16B7.10B11.16B11.40B5.90B2.63B
Stockholders Equity26.16B26.16B14.29B10.64B7.64B3.25B
Cash Flow
Free Cash Flow0.004.12B4.97B1.11B2.72B1.51B
Operating Cash Flow0.004.42B5.08B1.30B2.97B1.72B
Investing Cash Flow0.00-6.83B-3.27B-8.93B-1.60B-242.49M
Financing Cash Flow0.002.88B-662.00M3.33B2.33B-1.32B

Indegene Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price552.95
Price Trends
50DMA
567.00
Negative
100DMA
573.60
Negative
200DMA
575.61
Negative
Market Momentum
MACD
-2.42
Positive
RSI
41.81
Neutral
STOCH
18.54
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:INDGN, the sentiment is Negative. The current price of 552.95 is below the 20-day moving average (MA) of 571.45, below the 50-day MA of 567.00, and below the 200-day MA of 575.61, indicating a bearish trend. The MACD of -2.42 indicates Positive momentum. The RSI at 41.81 is Neutral, neither overbought nor oversold. The STOCH value of 18.54 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:INDGN.

Indegene Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
₹535.65B30.712.04%8.11%10.73%
66
Neutral
₹320.86B39.380.73%17.09%21.20%
66
Neutral
₹132.81B30.400.36%
65
Neutral
₹335.65B45.031.35%-1.19%-17.92%
61
Neutral
$37.18B12.37-10.20%1.83%8.50%-7.62%
55
Neutral
₹1.41T28.023.09%2.88%79.99%
51
Neutral
₹311.76B120.98%66.43%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:INDGN
Indegene Limited
552.95
-124.58
-18.39%
IN:ITI
ITI Limited
337.75
91.70
37.27%
IN:KPITTECH
KPIT Technologies Limited
1,162.05
-557.79
-32.43%
IN:MPHASIS
Mphasis Limited
2,808.05
10.44
0.37%
IN:TATAELXSI
Tata Elxsi Limited
5,573.15
-2,102.35
-27.39%
IN:TECHM
Tech Mahindra Limited
1,466.30
-110.78
-7.02%

Indegene Limited Corporate Events

Indegene Limited Publishes Q2 2025 Financial Results
Aug 2, 2025

Indegene Limited has announced the publication of its financial results for the quarter ending June 30, 2025, in prominent newspapers. This move aligns with regulatory requirements and aims to ensure transparency and accessibility of financial information for stakeholders, potentially impacting investor confidence and market positioning.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 08, 2025